Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Prediction of time to hormonal treatment failure in metastatic castrate-sensitive prostate cancer with 18F-FDG PET/CT.

Jadvar H, Velez E, Desai B, Ji L, Colletti PM, Quinn DI.

J Nucl Med. 2019 Mar 29. pii: jnumed.118.223263. doi: 10.2967/jnumed.118.223263. [Epub ahead of print]

PMID:
30926649
2.

Baseline 18F-FDG PET/CT parameters as imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancer.

Jadvar H, Desai B, Ji L, Conti PS, Dorff TB, Groshen SG, Pinski JK, Quinn DI.

J Nucl Med. 2013 Aug;54(8):1195-201. doi: 10.2967/jnumed.112.114116. Epub 2013 Jun 19.

3.

18F-FDG PET/CT predicts survival after 90Y transarterial radioembolization in unresectable hepatocellular carcinoma.

Jreige M, Mitsakis P, Van Der Gucht A, Pomoni A, Silva-Monteiro M, Gnesin S, Boubaker A, Nicod-Lalonde M, Duran R, Prior JO, Denys A, Schaefer N.

Eur J Nucl Med Mol Imaging. 2017 Jul;44(7):1215-1222. doi: 10.1007/s00259-017-3653-0. Epub 2017 Feb 23.

PMID:
28233086
4.

Preoperative Standardized Uptake Value of Metastatic Lymph Nodes Measured by 18F-FDG PET/CT Improves the Prediction of Prognosis in Gastric Cancer.

Song BI, Kim HW, Won KS, Ryu SW, Sohn SS, Kang YN.

Medicine (Baltimore). 2015 Jul;94(26):e1037. doi: 10.1097/MD.0000000000001037.

5.

Pretreatment F-18 FDG PET/CT Parameters to Evaluate Progression-Free Survival in Gastric Cancer.

Kim J, Lim ST, Na CJ, Han YH, Kim CY, Jeong HJ, Sohn MH.

Nucl Med Mol Imaging. 2014 Mar;48(1):33-40. doi: 10.1007/s13139-013-0243-3. Epub 2013 Nov 28.

6.

Prognostic implication of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with recurrent papillary thyroid cancer.

Kang JH, Jung DW, Pak KJ, Kim IJ, Kim HJ, Cho JK, Shin SC, Wang SG, Lee BJ.

Head Neck. 2018 Jan;40(1):94-102. doi: 10.1002/hed.24967. Epub 2017 Nov 11.

PMID:
29130586
7.

Lymph node standardized uptake values at pre-treatment 18F-fluorodeoxyglucose positron emission tomography as a valuable prognostic factor for distant metastasis in nasopharyngeal carcinoma.

Jeong Y, Baek S, Park JW, Joo JH, Kim JS, Lee SW.

Br J Radiol. 2017 Mar;90(1071):20160239. doi: 10.1259/bjr.20160239. Epub 2016 Dec 23.

8.

High prognostic value of 18F-FDG PET for metastatic gastroenteropancreatic neuroendocrine tumors: a long-term evaluation.

Bahri H, Laurence L, Edeline J, Leghzali H, Devillers A, Raoul JL, Cuggia M, Mesbah H, Clement B, Boucher E, Garin E.

J Nucl Med. 2014 Nov;55(11):1786-90. doi: 10.2967/jnumed.114.144386. Epub 2014 Oct 6.

9.

Comparison of the prognostic values of 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in patients with well-differentiated neuroendocrine tumor.

Sharma P, Naswa N, Kc SS, Alvarado LA, Dwivedi AK, Yadav Y, Kumar R, Ammini AC, Bal C.

Eur J Nucl Med Mol Imaging. 2014 Dec;41(12):2194-202. doi: 10.1007/s00259-014-2850-3. Epub 2014 Jul 17.

PMID:
25030618
10.

Prognostic value of SUVmax measured by pretreatment 18F-FDG PET/CT in patients with primary gastric lymphoma.

Hwang JP, Lim I, Byun BH, Kim BI, Choi CW, Lim SM.

Nucl Med Commun. 2016 Dec;37(12):1267-1272.

PMID:
27482643
11.

Prognostic value of maximum standardized uptake value measured by pretreatment 18F-FDG PET/CT in locally advanced head and neck squamous cell carcinoma.

Cacicedo J, Fernandez I, Del Hoyo O, Navarro A, Gomez-Iturriaga A, Pijoan JI, Martinez-Indart L, Escudero J, Gomez-Suarez J, de Zarate RO, Perez JF, Bilbao P, Rades D.

Clin Transl Oncol. 2017 Nov;19(11):1337-1349. doi: 10.1007/s12094-017-1674-6. Epub 2017 May 24.

PMID:
28540535
12.

Prospective evaluation of qualitative and quantitative ¹⁸F-FDG PET-CT parameters for predicting survival in recurrent carcinoma of the cervix.

Maharjan S, Sharma P, Patel CD, Sharma DN, Dhull VS, Jain SK, Thulkar S, Malhotra A, Kumar R.

Nucl Med Commun. 2013 Aug;34(8):741-8. doi: 10.1097/MNM.0b013e3283622f0d.

PMID:
23676840
13.

Whole-Body Metabolic Tumor Volume, as Determined by (18)F-FDG PET/CT, as a Prognostic Factor of Outcome for Patients With Breast Cancer Who Have Distant Metastasis.

Son SH, Lee SW, Jeong SY, Song BI, Chae YS, Ahn BC, Lee J.

AJR Am J Roentgenol. 2015 Oct;205(4):878-85. doi: 10.2214/AJR.14.13906. Epub 2015 Jul 23.

PMID:
26204115
14.

Role of Various Metabolic Parameters Derived From Baseline 18F-FDG PET/CT as Prognostic Markers in Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy.

Sharma A, Mohan A, Bhalla AS, Sharma MC, Vishnubhatla S, Das CJ, Pandey AK, Sekhar Bal C, Patel CD, Sharma P, Agarwal KK, Kumar R.

Clin Nucl Med. 2018 Jan;43(1):e8-e17. doi: 10.1097/RLU.0000000000001886.

PMID:
29112011
15.

Prognostic significance of standardized uptake value and metabolic tumour volume on ¹⁸F-FDG PET/CT in oropharyngeal squamous cell carcinoma.

Kim JW, Oh JS, Roh JL, Kim JS, Choi SH, Nam SY, Kim SY.

Eur J Nucl Med Mol Imaging. 2015 Aug;42(9):1353-61. doi: 10.1007/s00259-015-3051-4. Epub 2015 Jun 12.

PMID:
26067088
16.

Clinical and prognostic value of 18F-FDG-PET/CT in restaging of pancreatic cancer.

Albano D, Familiari D, Gentile R, Scalisi S, Midiri F, Messina M, Spada M, Fornito MC, Galia M, Midiri M, Alongi P.

Nucl Med Commun. 2018 Aug;39(8):741-746. doi: 10.1097/MNM.0000000000000862.

PMID:
29782393
17.

18F-FDG PET/CT as an Indicator of Survival in Ewing Sarcoma of Bone.

Salem U, Amini B, Chuang HH, Daw NC, Wei W, Haygood TM, Madewell JE, Costelloe CM.

J Cancer. 2017 Aug 25;8(15):2892-2898. doi: 10.7150/jca.20077. eCollection 2017.

18.

Differentiation of metastatic vs degenerative joint disease using semi-quantitative analysis with (18)F-NaF PET/CT in castrate resistant prostate cancer patients.

Muzahir S, Jeraj R, Liu G, Hall LT, Rio AM, Perk T, Jaskowiak C, Perlman SB.

Am J Nucl Med Mol Imaging. 2015 Jan 15;5(2):162-8. eCollection 2015.

19.

FDG Avidity and Tumor Burden: Survival Outcomes for Patients With Recurrent Breast Cancer.

Taghipour M, Wray R, Sheikhbahaei S, Wright JL, Subramaniam RM.

AJR Am J Roentgenol. 2016 Apr;206(4):846-55. doi: 10.2214/AJR.15.15106. Epub 2016 Feb 25.

PMID:
27003053
20.

Prognostic value of SUVmax measured by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography with Computed Tomography in Patients with Pancreatic Cancer.

Hwang JP, Lim I, Chang KJ, Kim BI, Choi CW, Lim SM.

Nucl Med Mol Imaging. 2012 Sep;46(3):207-14. doi: 10.1007/s13139-012-0151-y. Epub 2012 Jun 30.

Supplemental Content

Support Center